TIDMAGL
Angle PLC
07 November 2019
For immediate release 7 November 2019
ANGLE plc ("the Company")
LEADING CANCER CENTRE DEMONSTRATES USE OF PARSORTIX IN
MELANOMA
Parsortix harvests cancer cells from blood for analysis where
cell surface markers systems are limited
CTCs predicted relapse earlier than standard of care imaging
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that leading European cancer
centre, University Medical Centre Hamburg-Eppendorf (UKE), Germany
has published results of work demonstrating that ANGLE's
Parsortix(R) system can be used as a liquid biopsy to investigate
prediction and monitoring of therapy responses for melanoma
patients.
Malignant melanoma is the deadliest form of skin cancer, with a
global incidence of 290,000 per annum and 970,000 people living
with the disease (source Globocan 2018). The disease is highly
heterogeneous and the publication states that "reliable biomarkers,
which allow the prediction of therapeutic response and/or the
development of therapeutic resistance as early as possible, are
urgently needed".
The results of the study by UKE have been published in the
renowned peer-reviewed medical journal, Cancers. In the research,
UKE used Parsortix over a five-year period, with follow-up in some
cases for three years, the results showing that Parsortix can
harvest circulating tumor cells (CTCs) from some melanoma patients,
where other cell surface marker dependent systems are unable to do
so.
This development holds the potential to shift current treatment
options for melanoma. Analysis of CTCs harvested from melanoma
patients opens up the potential for Parsortix's use as a companion
diagnostic to select appropriate therapies and regularly monitor
patients with melanoma, ensuring any potential relapse is flagged
early and patients can receive the best treatment possible. The
researchers demonstrated that the presence of CTCs in a patient's
blood sample (where in a previous sample they had been absent)
indicated relapse earlier than standard of care imaging
techniques.
ANGLE's Founder and Chief Executive, Andrew Newland,
commented:
"As the deadliest form of skin cancer, there is a clear need for
reliable biomarkers in melanoma. Initially, these can be used in
drug trials where the detection of likely responders to the drug is
essential and a key commercial need for pharma companies.
Ultimately there is the potential for routine clinical use as a
companion diagnostic in melanoma."
A copy of the Cancers publication is available on ANGLE's
website here
https://angleplc.com/library/publications/.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen as being a complete cell they allow
DNA, RNA and protein analysis and the live cells harvested can be
cultured. The Parsortix technology is the subject of 24 granted
patents in Europe, the United States, China, Australia, Canada,
India, Japan and Mexico with three extensive families of patents
are being progressed worldwide. The Parsortix system has a CE Mark
in Europe for the indicated use and FDA clearance is in process for
the United States with a 400 subject clinical study and associated
analytical studies in metastatic breast cancer. ANGLE is seeking to
be the first ever FDA cleared CTC harvesting system and only the
third ever FDA cleared liquid biopsy test. ANGLE has already
undertaken two separate 200 subject clinical studies under a
program designed to develop an ovarian cancer pelvic mass triage
test, with the results showing best in class accuracy (ROC-AUC) of
95.1%. The pelvic mass triage assay has undergone further
refinement and optimisation, and is currently in the process of a
200 patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (ROC-AUC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
26 peer-reviewed publications and numerous publicly available
posters, available on our website.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALLFLTLELRIIA
(END) Dow Jones Newswires
November 07, 2019 02:01 ET (07:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024